Investing
Investing Cash Flow
Year-over-year, this metric declined by 122.5%, from $113.77M to -$25.54M. Over 3 years (FY 2021 to FY 2025), Investing Cash Flow shows an upward trend with a 20.1% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Typically negative for growing companies as they reinvest cash; a positive value suggests the company is liquidating assets faster than it is buying them.
Detailed definition
The aggregate sum of all cash inflows and outflows related to a company's long-term investments and capital assets. It s...
Peer comparison
Mature companies with high cash flow often show large negative values here as they recycle profits into new growth or financial instruments.
Metric ID:
net_cash_from_investingHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $157.02M | -$88.27M | -$413.41M | -$147.42M | $142.79M | $313.89M | -$76.22M | -$8.71M | -$10.76M | -$240.66M | -$67.62M | $33.94M | -$30.25M | -$52.91M | $113.77M | -$141.38M | $501.11M | $0.00 | -$25.54M |
| QoQ Change | — | -156.2% | -368.3% | +64.3% | +196.9% | +119.8% | -124.3% | +88.6% | -23.5% | <-999% | +71.9% | +150.2% | -189.1% | -74.9% | +315.0% | -224.3% | +454.4% | -100.0% | — |
| YoY Change | — | — | — | — | -9.1% | +455.6% | +48.3% | -106.1% | -103.4% | — | +11.3% | +489.5% | -181.0% | +78.0% | +268.2% | -516.6% | >999% | +100.0% | -122.5% |
Range-$413.41M – $501.11M
CAGR-33.2%
Avg YoY Growth+154.9%
Median YoY Growth+29.8%
Current Streak2 quarters decline
Investing Cash Flow at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's investing cash flow?
- Alnylam Pharmaceuticals (ALNY) reported investing cash flow of -$25.54M in Q1 2026.
- How has Alnylam Pharmaceuticals's investing cash flow changed year-over-year?
- Alnylam Pharmaceuticals's investing cash flow decreased by 122.5% year-over-year, from $113.77M to -$25.54M.
- What is the long-term trend for Alnylam Pharmaceuticals's investing cash flow?
- Over 3 years (2021 to 2025), Alnylam Pharmaceuticals's investing cash flow has grown at a 20.1% compound annual growth rate (CAGR), from -$273.30M to $473.50M.
- What does investing cash flow mean?
- The total net change in cash resulting from buying and selling long-term assets and investments.